Guggenheim: SGMO's update this week was largely consistent with prior messaging, in our view, so we think the -14% vs. NBI up ~0.7% after its investor presentation was an overreaction.
SGMO's update this week was largely consistent with prior messaging, in our view, so we think the -14% vs. NBI up ~0.7% after its investor presentation was an overreaction. Mgmt continued to indicate that its approach to data disclosure around open-label studies will be more conservative. That said, data from SB-913 and SB-318 will be presented at the upcoming WORLDSymposium in early February. In MPS II (the more robust dataset) we'll be focused on data from the higher dose cohort and on the new, more sensitive enzyme assay which, if positive, could help validate the IVPRP approach. Later in the year we could also get data from hemophilia A and B-thal, and the co is advancing/ initiating several other trials this year. Impact to our thesis? No change, for now - maintain NEUTRAL. SGMO’s diversified tech platform and pipeline provides many shots on goal – it’s a basket approach in a single company. At this point though, we are awaiting more clear POC in the clinic to better assess the value of the various programs and the platform tech overall. There are several opportunities for that this year given the number of clinical trials and data readouts expected. While we remain NEUTRAL, we do think recent underperformance could set shares up well if positive data emerges throughout the year. Upcoming events: • SB-913 (MPS II): Data update is expected at WORLDSymposium (Feb 4-8, Orlando). The co is scheduled to present 24 week safety and biochemical changes (with a much sensitive assay) at 24 weeks in the 6 patients. • SB-318 (MPS I): At WORLD the co will present preliminary safety and some efficacy data at up to 4 weeks in the 3 treated patients. • SB-525 (hemophilia A): SGMO plans to present data in 2019, after the trial completes the dose escalation phase • SB-FIX (hemophilia B): The trial is enrolling directly at the 5e13 vg/kg cohort and the company expects early data in 2019 • ST-400 (β-thal): ONCE expects initial data in 2019 • BIVV-003 (sickle cell disease): The company expects data readout in 2019 • Clinical trial initiations expected in 2019 include ST-920 in Fabry disease, Tx200 for HLAA2 renal transplant (CTA), and an IND filing for an allogeneic CD19 (w/ GILD)
Under: Been on the sidelines for a bit holding (building) cash. Now that "BIGLEY" has rolled out the tax plan its time to jump in.
Dec 21, 2017 19:06:02 GMT -6
martyc: Looks like you are buying Msft again!
Dec 15, 2017 11:23:29 GMT -6
martyc: The news that Trump called Rupert to congratulate him sure seems to indicate that this is heading to approval
Dec 15, 2017 11:22:23 GMT -6
Under: DIS finally getting some traction.?
Dec 14, 2017 17:08:45 GMT -6
martyc: I took an entry level position in DIS. Will add eventually to overweight when it becomes clearer that the deal will go thru. Can't believe how well positioned they will be. 60% Hulu. 20% of content watched on NFLX they can pull. More in thread
Dec 14, 2017 11:05:16 GMT -6
Under: Great posts on $DIS
Dec 13, 2017 17:50:49 GMT -6
Under: $ROKU Citron on a war path.
Nov 28, 2017 15:11:20 GMT -6
Under: $HAS takeover bid for $MAT?
Nov 10, 2017 16:16:07 GMT -6
martyc: Not looking like the market will provide any discounted opp for SGMO. Call was just too professional and all signs indicate they are on a great path for commercialization. Happy with core but wish I had some trading shs
Nov 10, 2017 9:04:05 GMT -6
martyc: For anyone looking to find an entry point into SGMO, I'm almost hoping is sells off in next few days so I can add more. They are really clicking but the fact they haven't signed new deals might cause some to exit. Watching as I have room for trading shs
Nov 9, 2017 18:28:09 GMT -6
martyc: Been an interesting ride so far. I figured the Bears would be about this good but hoped the O wouldn't look so lame. Another building yr but still possible to get to 8-8 IMO
Nov 9, 2017 18:26:08 GMT -6
Under: whats up with your Bears this year Marty?
Nov 9, 2017 17:35:25 GMT -6
martyc: Hope you were long ROKU. I wanted to see Q first so missed out
Nov 9, 2017 7:08:53 GMT -6